Oral anticoagulant use and clinical outcomes in elderly Japanese patients: findings from the SAKURA AF Registry.


Journal

Heart and vessels
ISSN: 1615-2573
Titre abrégé: Heart Vessels
Pays: Japan
ID NLM: 8511258

Informations de publication

Date de publication:
Dec 2019
Historique:
received: 05 03 2019
accepted: 31 05 2019
pubmed: 12 6 2019
medline: 25 2 2020
entrez: 12 6 2019
Statut: ppublish

Résumé

Direct-acting oral anticoagulants (DOACs) are widely used in aged Japanese patients with atrial fibrillation (AF), but outcome data for such patients are limited. We compared outcomes between 1895 (58.5%) patients aged < 75 years (non-elderly), 1078 (33.3%) 75-84 years (elderly) and 264 (8.2%) ≥ 85 years (very elderly) enrolled in a prospective multicenter registry. Kaplan-Meier analysis (median follow-up: 39.3 months) revealed a significantly high incidence of stroke/systemic embolism (SE) among the very elderly relative to that among the non-elderly or elderly (3.2 vs. 1.2 and 1.5 events per 100 patient-years, p < 0.001). Major bleeding in the non-elderly group was significantly infrequent relative to that among the elderly or very elderly group (1.1 vs. 1.6 vs. 1.8 events, p = 0.033). After multivariate adjustment, the stroke/SE incidence was comparable between DOAC and warfarin users, regardless of age, but major bleeding decreased significantly among very elderly DOAC users (adjusted HR 0.220, 95% CI 0.042-0.920). The greater increasing incidence of stroke/SE than major bleeding as patients age suggests that stroke prevention should outweigh the bleeding risk when anticoagulants are being considered for aged patients. Our data indicated that DOACs can be a therapeutic option for stroke prevention in very elderly patients.

Identifiants

pubmed: 31183513
doi: 10.1007/s00380-019-01446-6
pii: 10.1007/s00380-019-01446-6
doi:

Substances chimiques

Anticoagulants 0
Factor Xa Inhibitors 0
Warfarin 5Q7ZVV76EI

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

2021-2030

Références

Circ J. 2016;80(4):843-51
pubmed: 27001190
Pharmacoepidemiol Drug Saf. 2017 Nov;26(11):1367-1377
pubmed: 28752560
J Am Heart Assoc. 2016 Feb 23;5(2):
pubmed: 26908412
Circ J. 2018 Sep 25;82(10):2500-2509
pubmed: 30078823
Thromb Haemost. 2009 Mar;101(3):422-7
pubmed: 19277401
Pharmacotherapy. 2017 Oct;37(10):1221-1230
pubmed: 28730619
J Arrhythm. 2017 Aug;33(4):289-296
pubmed: 28765759
J Cardiol. 2013 Apr;61(4):260-6
pubmed: 23403369
Circulation. 2011 May 31;123(21):2363-72
pubmed: 21576658
J Am Heart Assoc. 2017 Jul 23;6(7):null
pubmed: 28736385
Circulation. 2018 Jul 3;138(1):37-47
pubmed: 29490992
Circulation. 2014 Jul 8;130(2):138-46
pubmed: 24895454
Circ J. 2017 Aug 25;81(9):1278-1285
pubmed: 28428449
J Am Med Dir Assoc. 2015 May 1;16(5):358-64
pubmed: 25680239
N Engl J Med. 2011 Sep 15;365(11):981-92
pubmed: 21870978
J Am Heart Assoc. 2016 May 20;5(5):
pubmed: 27207971
N Engl J Med. 2013 Nov 28;369(22):2093-104
pubmed: 24251359
Eur Heart J. 2014 Jul 21;35(28):1864-72
pubmed: 24561548
Circ J. 2013;77(3):632-8
pubmed: 23229461
Circ J. 2019 Mar 25;83(4):727-735
pubmed: 30726797
Thromb Haemost. 1993 Mar 1;69(3):236-9
pubmed: 8470047
JAMA Intern Med. 2016 Aug 1;176(8):1176-83
pubmed: 27379731
N Engl J Med. 2011 Sep 8;365(10):883-91
pubmed: 21830957
Int J Cardiol. 2009 Oct 2;137(2):102-7
pubmed: 18691774
N Engl J Med. 2009 Sep 17;361(12):1139-51
pubmed: 19717844
Drugs Aging. 2010 Mar 1;27(3):239-54
pubmed: 20210369
Int Heart J. 2018 Nov 28;59(6):1266-1274
pubmed: 30369576

Auteurs

Toshihiko Nishida (T)

Yokohama Chuo Hospital, Kanagawa, Japan.

Yasuo Okumura (Y)

Division of Cardiology, Nihon University Itabashi Hospital, Tokyo, Japan. okumura.yasuo@nihon-u.ac.jp.
Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Ohyaguchi-kamicho, Itabashi-ku, Tokyo, 173-8610, Japan. okumura.yasuo@nihon-u.ac.jp.

Katsuaki Yokoyama (K)

Department of Cardiology, Nihon University Hospital, Tokyo, Japan.

Naoya Matsumoto (N)

Department of Cardiology, Nihon University Hospital, Tokyo, Japan.

Eizo Tachibana (E)

Kawaguchi Municipal Medical Center, Saitama, Japan.

Keiichiro Kuronuma (K)

Kawaguchi Municipal Medical Center, Saitama, Japan.

Koji Oiwa (K)

Yokohama Chuo Hospital, Kanagawa, Japan.

Michiaki Matsumoto (M)

Yokohama Chuo Hospital, Kanagawa, Japan.

Toshiaki Kojima (T)

Sekishindo Hospital, Saitama, Japan.

Shoji Hanada (S)

TMG Asakadai Medical Center, Saitama, Japan.

Kazumiki Nomoto (K)

Tokyo Rinkai Hospital, Tokyo, Japan.

Kazumasa Sonoda (K)

Tokyo Rinkai Hospital, Tokyo, Japan.

Ken Arima (K)

Kasukabe Medical Center, Saitama, Japan.

Rikitake Kogawa (R)

Kasukabe Medical Center, Saitama, Japan.

Fumiyuki Takahashi (F)

Yasuda Hospital, Tokyo, Japan.

Tomobumi Kotani (T)

Makita General Hospital, Tokyo, Japan.

Kimie Ohkubo (K)

Itabashi Medical Association Hospital, Tokyo, Japan.

Seiji Fukushima (S)

Ukima Central Hospital, Tokyo, Japan.

Satoru Itou (S)

Itou Cardiovascular Clinic, Saitama, Japan.

Kunio Kondo (K)

Kondo Clinic, Tokyo, Japan.

Masaaki Chiku (M)

Keiai Clinic, Tokyo, Japan.

Yasumi Ohno (Y)

Ohno Medical Clinic, Tokyo, Japan.

Motoyuki Onikura (M)

Onikura Clinic, Chiba, Japan.

Atsushi Hirayama (A)

Division of Cardiology, Nihon University Itabashi Hospital, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH